Which is better EGFR-TKI followed by osimertinib: afatinib or gefitinib/erlotinib?
M Tamiya, A Tamiya, H Suzuki, K Moriizumi… - Anticancer …, 2019 - ar.iiarjournals.org
Background/Aim: Treatment with EGFR-tyrosine kinase inhibitor (TKI) shows a durable
response against NSCLC harboring EGFR mutation; however, treatment resistance occurs …
response against NSCLC harboring EGFR mutation; however, treatment resistance occurs …
[HTML][HTML] The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
YH Huang, JS Tseng, KH Hsu, KC Chen, KY Su… - Scientific Reports, 2021 - nature.com
The impact of different first-line epidermal growth factor receptor (EGFR)-tyrosine kinase
inhibitor (TKI) s to the clinical efficacy of osimertinib in EGFR-mutant non-small-cell lung …
inhibitor (TKI) s to the clinical efficacy of osimertinib in EGFR-mutant non-small-cell lung …
Efficacy and safety of osimertinib in treating EGFR‐mutated advanced NSCLC: A meta‐analysis
Osimertinib is the only Food and Drug Administration‐approved third‐generation epidermal
growth factor receptor (EGFR) tyrosine‐kinase inhibitor (TKI). A meta‐analysis was …
growth factor receptor (EGFR) tyrosine‐kinase inhibitor (TKI). A meta‐analysis was …
[HTML][HTML] Overall survival in stage IV EGFR mutation‑positive NSCLC: Comparing first‑, second‑and third‑generation EGFR‑TKIs
AK Vaid, A Gupta, G Momi - … journal of oncology, 2021 - spandidos-publications.com
Abstract A substantial (40‑60%) proportion of patients with non‑small cell lung carcinoma
(NSCLC) have epidermal growth factor receptor (EGFR) mutations, a crucial therapeutic …
(NSCLC) have epidermal growth factor receptor (EGFR) mutations, a crucial therapeutic …
[HTML][HTML] Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
SS Ramalingam, J Vansteenkiste… - … England Journal of …, 2020 - Mass Medical Soc
Background Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the
epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI …
epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI …
[HTML][HTML] Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib
N Yamamoto, T Mera, A Märten, MJ Hochmair - Advances in Therapy, 2020 - Springer
Introduction Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are
the standard of care for patients with EGFR mutation-positive non-small cell lung cancer …
the standard of care for patients with EGFR mutation-positive non-small cell lung cancer …
Efficacy and safety data of osimertinib in elderly patients with NSCLC who harbor the EGFR T790M mutation after failure of initial EGFR-TKI treatment
H Furuta, T Uemura, T Yoshida, M Kobara… - Anticancer …, 2018 - ar.iiarjournals.org
Background/Aim: The aim of this study was to evaluate the safety and efficacy of osimertinib
for elderly patients, since the data remain limited. Patients and Methods: A total of 77 …
for elderly patients, since the data remain limited. Patients and Methods: A total of 77 …
Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA
S Ramalingam, T Reungwetwattana… - Annals of …, 2017 - annalsofoncology.org
Background: Osimertinib is a third-generation, CNS-active EGFR-TKI that potently and
selectively inhibits both EGFRm and EGFR T790M resistance mutations. Pre-and early …
selectively inhibits both EGFRm and EGFR T790M resistance mutations. Pre-and early …
[HTML][HTML] Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG)
Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are
standard of care for EGFR mutation-positive non-small cell lung cancer (NSCLC). However …
standard of care for EGFR mutation-positive non-small cell lung cancer (NSCLC). However …
[HTML][HTML] Osimertinib versus comparator EGFR TKI as first-line treatment for EGFR-mutated advanced NSCLC: FLAURA China, a randomized study
Y Cheng, Y He, W Li, H Zhang, Q Zhou, B Wang… - Targeted …, 2021 - Springer
Background In the global FLAURA study, first-line osimertinib, a third-generation irreversible
tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR), significantly …
tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR), significantly …